Company / Shareholders' Equity
Avalo Therapeutics, Inc. Shareholders' Equity History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$83.0M
FY2025
5-year range
-$10.9M / $133.0M
FY2021-FY2025
Trend
-37.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 9 years, ranging from -$11M in FY2022 to $133M in FY2024.
Based on SEC 10-K filings.
$83M in FY2025 with a 5-year CAGR of +27.6%.
Improved from $7M to $83M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +27.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +27.6%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 37.6% year-over-year.
- Peak shareholders' equity was recorded in FY2024.
- Lowest shareholders' equity in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $83.0M | -37.6% |
| FY2024 | $133.0M | +1721.4% |
| FY2023 | $7.3M | +166.9% |
| FY2022 | -$10.9M | -147.3% |
| FY2021 | $23.1M | -6.0% |
| FY2020 | $24.6M | +17.0% |
| FY2019 | $21.0M | +0.4% |
| FY2018 | $20.9M | -25.0% |
| FY2017 | $27.9M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026